التداخل بين تادالافيل وفيريسيغوات

PDE-5 Inhibitors: Concomitant use is not recommended.

PDE-5 Inhibitors Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension [see Clinical Pharmacology (12.2) ] .

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated.

When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased.

Patients with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors.

Patients with severely impaired autonomic control of blood pressure may be particularly sensitive to the actions of vasodilators, including PDE5 inhibitors.

PDE5 inhibitors, including CIALIS, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects.